Emergent Biosolutions (NYSE:EBS) Releases Quarterly Earnings Results, Beats Expectations By $0.46 EPS

Emergent Biosolutions (NYSE:EBS) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.46, FiscalAI reports. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.64%. The firm had revenue of $156.10 million during the quarter, compared to analysts’ expectations of $145.00 million.

Here are the key takeaways from Emergent Biosolutions’ conference call:

• Emergent reported Q1 revenue of $156 million (above the high end of guidance) and an Adjusted EBITDA of $36 million with a 23% margin, while cash and liquidity improved to $160M and $260M respectively and net debt fell ~22% year‑over‑year.
• The April 2026 debt refinancing extended maturities (out to 2031), lowered interest costs, added a $75M delayed‑draw term loan and a $50M revolver, which management says enhances liquidity and financial flexibility for growth.
• Management emphasized growth levers including international MCM expansion (internationals were ~37% of MCM revenue in Q1), new NARCAN line extensions (carrying case and multi‑pack), strategic manufacturing partnerships (Substipharm, SAB) and continued business‑development/acquisition activity.
• Emergent expects a $50.4 million cash outflow in Q2 as an accrued acquisition obligation to Ridgeback related to the Ebanga/BARDA contract, which management has recorded as a current liability.

Emergent Biosolutions Stock Up 3.0%

NYSE:EBS traded up $0.25 during midday trading on Friday, reaching $8.48. 1,407,261 shares of the stock traded hands, compared to its average volume of 558,687. Emergent Biosolutions has a 12-month low of $4.71 and a 12-month high of $14.06. The business has a 50-day moving average of $8.54 and a two-hundred day moving average of $10.29. The company has a debt-to-equity ratio of 1.09, a quick ratio of 2.41 and a current ratio of 5.01. The stock has a market capitalization of $437.96 million, a PE ratio of 10.10 and a beta of 2.33.

Analyst Upgrades and Downgrades

EBS has been the subject of several research reports. Wall Street Zen cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. HC Wainwright lowered their price target on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, March 9th. Finally, Weiss Ratings cut shares of Emergent Biosolutions from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Emergent Biosolutions currently has an average rating of “Hold” and an average target price of $12.00.

Emergent Biosolutions News Roundup

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: Q1 earnings beat and stronger margins — Emergent reported $0.21 EPS vs. a consensus loss and revenue of $156.1M above estimates; management highlighted improving profitability and returned a positive ROE. The better‑than‑expected quarter and upbeat commentary are the primary drivers of the stock move today. Earnings Press Release
• Positive Sentiment: Regulatory win expands market for ACAM2000 — Singapore’s HSA approved an expanded indication for ACAM2000 to include prevention of mpox in high‑risk adults, which supports incremental product sales outside the U.S. and validates market access progress. Singapore Approval
• Positive Sentiment: Earnings call emphasized “turnaround momentum” — Management highlighted cost discipline, margin recovery and business mix improvement on the call, reinforcing investor expectations for continued operational improvement. Earnings Call Highlights
• Neutral Sentiment: Board and incentive plan changes approved — Shareholders backed board/incentive adjustments at the annual meeting, reducing governance uncertainty but with limited immediate financial impact. This supports corporate stability. Shareholder Vote
• Neutral Sentiment: FY and Q2 revenue guidance given with mixed signal — Management updated FY26 revenue to $720M–$760M (consensus ~$740M) and Q2 revenue to $170M–$185M (consensus ~$182M). The ranges include the consensus midpoint but Q2 guidance is slightly below street expectations, leaving guidance impact mixed. Q1 Report & Guidance
• Negative Sentiment: Market reaction to a new deal with SAB was tepid — Coverage noted the stock inched lower on a new SAB agreement, suggesting investors may be cautious about deal terms or near‑term dilution/earnings impact. This likely weighed on sentiment for some holders. SAB Deal Reaction

Institutional Investors Weigh In On Emergent Biosolutions

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp lifted its position in Emergent Biosolutions by 10.2% during the fourth quarter. State Street Corp now owns 2,696,375 shares of the biopharmaceutical company’s stock valued at $33,327,000 after acquiring an additional 250,616 shares during the last quarter. Millennium Management LLC lifted its position in Emergent Biosolutions by 68.9% during the first quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock valued at $12,162,000 after acquiring an additional 1,020,582 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Emergent Biosolutions by 5.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,252,605 shares of the biopharmaceutical company’s stock valued at $27,841,000 after acquiring an additional 112,265 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Emergent Biosolutions by 17.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,618,903 shares of the biopharmaceutical company’s stock valued at $20,010,000 after acquiring an additional 237,153 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in Emergent Biosolutions by 14.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,132,305 shares of the biopharmaceutical company’s stock valued at $9,987,000 after acquiring an additional 145,632 shares during the last quarter. Hedge funds and other institutional investors own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.